Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Eileen S. Walsh is active.

Publication


Featured researches published by Eileen S. Walsh.


Journal of Medicinal Chemistry | 2008

Kinesin spindle protein (KSP) inhibitors. 9. Discovery of (2S)-4-(2,5-difluorophenyl)-n-[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]-2-(hydroxymethyl)-N-methyl-2-phenyl-2,5-dihydro-1H-pyrrole-1-carboxamide (MK-0731) for the treatment of taxane-refractory cancer.

Christopher D. Cox; Paul J. Coleman; Michael J. Breslin; David B. Whitman; Robert M. Garbaccio; Mark E. Fraley; Carolyn A. Buser; Eileen S. Walsh; Kelly Hamilton; Michael D. Schaber; Robert B. Lobell; Weikang Tao; Joseph P. Davide; Ronald E. Diehl; Marc Abrams; Vicki J. South; Hans E. Huber; Maricel Torrent; Thomayant Prueksaritanont; Chunze Li; Donald E. Slaughter; Elizabeth Mahan; Carmen Fernandez-Metzler; Youwei Yan; Lawrence C. Kuo; Nancy E. Kohl; George D. Hartman

Inhibition of kinesin spindle protein (KSP) is a novel mechanism for treatment of cancer with the potential to overcome limitations associated with currently employed cytotoxic agents. Herein, we describe a C2-hydroxymethyl dihydropyrrole KSP inhibitor ( 11) that circumvents hERG channel binding and poor in vivo potency, issues that limited earlier compounds from our program. However, introduction of the C2-hydroxymethyl group caused 11 to be a substrate for cellular efflux by P-glycoprotein (Pgp). Utilizing knowledge garnered from previous KSP inhibitors, we found that beta-fluorination modulated the p K a of the piperidine nitrogen and reduced Pgp efflux, but the resulting compound ( 14) generated a toxic metabolite in vivo. Incorporation of fluorine in a strategic, metabolically benign position by synthesis of an N-methyl-3-fluoro-4-(aminomethyl)piperidine urea led to compound 30 that has an optimal in vitro and metabolic profile. Compound 30 (MK-0731) was recently studied in a phase I clinical trial in patients with taxane-refractory solid tumors.


Bioconjugate Chemistry | 2013

Endosomolytic Bioreducible Poly(amido amine disulfide) Polymer Conjugates for the in Vivo Systemic Delivery of siRNA Therapeutics

Rubina Parmar; Marina Busuek; Eileen S. Walsh; Karen R. Leander; Bonnie J. Howell; Laura Sepp-Lorenzino; Eric Kemp; Louis S. Crocker; Anthony Leone; Christopher J. Kochansky; Brian A. Carr; Robert M. Garbaccio; Steven L. Colletti; Weimin Wang

Efficient siRNA delivery is dependent not only on the ability of the delivery vehicle to target a specific organ but also on its ability to enable siRNA entry into the cytoplasm of the target cells. Polymers with endosomolytic properties are increasingly being used as siRNA delivery vehicles due to their potential to facilitate endosomal escape and intracellular delivery. Addition of disulfide bonds in the backbone of these polymers was expected to provide degradability through reduction by glutathione in cytosol. This paper describes the synthesis of new endosomolytic bioreducible poly(amido amine disulfide) polymers whose lytic potential can be masked at physiological pH, but can be restored at acidic endosomal pH. These polymer conjugates gave good in vitro knockdown (KD) and did not demonstrate cytotoxicity in a MTS assay. Efficient mRNA KD for apolipoprotein B in mouse liver was observed with these polyconjugates following intravenous dosing.


Bioorganic & Medicinal Chemistry Letters | 2012

Pyridyl aminothiazoles as potent inhibitors of Chk1 with slow dissociation rates.

Vadim Y. Dudkin; Keith Rickert; Constantine Kreatsoulas; Cheng Wang; Kenneth L. Arrington; Mark E. Fraley; George D. Hartman; Yowei Yan; Mari Ikuta; Steven M. Stirdivant; Robert A. Drakas; Eileen S. Walsh; Kelly Hamilton; Carolyn A. Buser; Robert B. Lobell; Laura Sepp-Lorenzino

Pyridyl aminothiazoles comprise a novel class of ATP-competitive Chk1 inhibitors with excellent inhibitory potential. Modification of the core with ethylenediamine amides provides compounds with low picomolar potency and very high residence times. Investigation of binding parameters of such compounds using X-ray crystallography and molecular dynamics simulations revealed multiple hydrogen bonds to the enzyme backbone as well as stabilization of the conserved water molecules network in the hydrophobic binding region.


Bioconjugate Chemistry | 2014

Novel endosomolytic poly(amido amine) polymer conjugates for systemic delivery of siRNA to hepatocytes in rodents and nonhuman primates.

Rubina Parmar; Micheal Poslusney; Marina Busuek; J. Michael Williams; Robert M. Garbaccio; Karen R. Leander; Eileen S. Walsh; Bonnie J. Howell; Laura Sepp-Lorenzino; Sean Riley; Mihir Patel; Eric Kemp; Andrew H. Latham; Anthony Leone; Eric Soli; Rob S. Burke; Brian A. Carr; Steven L. Colletti; Weimin Wang

The application of small interfering (si)RNAs as potential therapeutic agents requires safe and effective methods for their delivery to the cytoplasm of the target cells and tissues. Recent studies have shown significant progress in the development of targeting reagents that facilitate the recognition of, and siRNA delivery to, specific cell types. Among recently reported delivery approaches, polymers with amphipathic properties have been used to enable endosome escape and cytosolic delivery. Here, we describe a linear amphipathic poly(amido amine) polymer conjugate system for the efficient siRNA delivery in vitro and in vivo. This polymer contains a novel amine bearing bis-acrylamide monomer designed for increasing amine density, which resulted in substantial improvement in liver uptake and RNAi activity compared to our previously reported poly(amido amine disulfide) polymer.1 The activity for this liver targeted delivery system was demonstrated in rodents and nonhuman primates.


Bioorganic & Medicinal Chemistry Letters | 2002

Dual inhibitors of farnesyltransferase and geranylgeranyltransferase i

Diem N. Nguyen; Craig A. Stump; Eileen S. Walsh; Christine Fernandes; Joseph P. Davide; Michelle Ellis-Hutchings; Ronald G. Robinson; Theresa M. Williams; Robert B. Lobell; Hans E. Huber; Carolyn A. Buser

Compound 1 has been shown to be a dual prenylation inhibitor with FPTase (IC50=2 nM) and GGPTase-I (IC50=95 nM). Analogues of 1, which replaced the cyanophenyl group with various biaryls, led to the discovery of highly potent dual FPTase/GGPTase-I inhibitors. 4-trifluoromethylphenyl, trifluoropentynyl, and trifluoropentyl were identified as good p-cyano replacements.


Bioorganic & Medicinal Chemistry Letters | 2001

2-Arylindole-3-acetamides: FPP-competitive inhibitors of farnesyl protein transferase

B. Wesley Trotter; Amy G. Quigley; William C. Lumma; John T. Sisko; Eileen S. Walsh; Christian S. Hamann; Ronald G. Robinson; Hema Bhimnathwala; D. Garrett Kolodin; Wei Zheng; Carolyn A. Buser; Hans E. Huber; Robert B. Lobell; Nancy E. Kohl; Theresa M. Williams; Samuel L. Graham; Christopher J. Dinsmore

A series of 2-arylindole-3-acetamide farnesyl protein transferase inhibitors has been identified. The compounds inhibit the enzyme in a farnesyl pyrophosphate-competitive manner and are selective for farnesyl protein transferase over the related enzyme geranylgeranyltransferase-I. A representative member of this series of inhibitors demonstrates equal effectiveness against HDJ-2 and K-Ras farnesylation in a cell-based assay when geranylgeranylation is suppressed.


Bioorganic & Medicinal Chemistry Letters | 2012

Pyridyl aminothiazoles as potent Chk1 inhibitors: Optimization of cellular activity

Vadim Y. Dudkin; Cheng Wang; Kenneth L. Arrington; Mark E. Fraley; George D. Hartman; Steven M. Stirdivant; Robert A. Drakas; Keith Rickert; Eileen S. Walsh; Kelly Hamilton; Carolyn A. Buser; James Hardwick; Weikang Tao; Stephen C. Beck; Xianzhi Mao; Robert B. Lobell; Laura Sepp-Lorenzino

Translation of significant biochemical activity of pyridyl aminothiazole class of Chk1 inhibitors into functional CEA potency required analysis and adjustment of both physical properties and kinase selectivity profile of the series. The steps toward optimization of cellular potency included elimination of CDK7 activity, reduction of molecular weight and polar surface area and increase in lipophilicity of the molecules in the series.


Bioorganic & Medicinal Chemistry Letters | 2001

Evaluation of amino acid-based linkers in potent macrocyclic inhibitors of farnesyl-protein transferase

Douglas C. Beshore; Ian M. Bell; Christopher J. Dinsmore; Carl F. Homnick; J.Christopher Culberson; Ronald G. Robinson; Christine Fernandes; Eileen S. Walsh; Marc T. Abrams; Hema Bhimnathwala; Joseph P. Davide; Michelle Ellis-Hutchings; Hans A Huber; Kenneth S. Koblan; Carolyn A. Buser; Nancy E. Kohl; Robert B. Lobell; I-Wu Chen; Debra McLoughlin; Timothy V. Olah; Samuel L. Graham; George D. Hartman; Theresa M. Williams

A series of amino acid-based linkers was used to investigate the effects of various substituents upon the potency, pharmacokinetic properties, and conformation of macrocyclic farnesyl-protein transferase inhibitors (FTIs). As a result of the studies described herein, highly potent FTIs with improved pharmacokinetic profiles have been identified.


Bioorganic & Medicinal Chemistry Letters | 2005

Kinesin spindle protein (KSP) inhibitors. Part 1: The discovery of 3,5-diaryl-4,5-dihydropyrazoles as potent and selective inhibitors of the mitotic kinesin KSP

Christopher D. Cox; Michael J. Breslin; Brenda J. Mariano; Paul J. Coleman; Carolyn A. Buser; Eileen S. Walsh; Kelly Hamilton; Hans E. Huber; Nancy E. Kohl; Maricel Torrent; Youwei Yan; Laurence C. Kuo; George D. Hartman


Journal of Medicinal Chemistry | 2002

3-Aminopyrrolidinone Farnesyltransferase Inhibitors: Design of Macrocyclic Compounds with Improved Pharmacokinetics and Excellent Cell Potency

Ian M. Bell; Steven N. Gallicchio; Marc T. Abrams; Lorena S. Beese; Douglas C. Beshore; Hema Bhimnathwala; Michael J. Bogusky; Carolyn A. Buser; J. Christopher Culberson; Joseph P. Davide; Michelle Ellis-Hutchings; Christine Fernandes; Jackson B. Gibbs; Samuel L. Graham; Kelly Hamilton; George D. Hartman; David C. Heimbrook; Carl F. Homnick; Hans E. Huber; Joel R. Huff; Kelem Kassahun; Kenneth S. Koblan; Nancy E. Kohl; Robert B. Lobell; Joseph J. Lynch; Ronald G. Robinson; A. David Rodrigues; Jeffrey S. Taylor; Eileen S. Walsh; and Theresa M. Williams

Collaboration


Dive into the Eileen S. Walsh's collaboration.

Top Co-Authors

Avatar

Carolyn A. Buser

United States Military Academy

View shared research outputs
Top Co-Authors

Avatar

George D. Hartman

United States Military Academy

View shared research outputs
Top Co-Authors

Avatar

Robert B. Lobell

United States Military Academy

View shared research outputs
Top Co-Authors

Avatar

Robert M. Garbaccio

United States Military Academy

View shared research outputs
Top Co-Authors

Avatar

Mark E. Fraley

United States Military Academy

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Weikang Tao

United States Military Academy

View shared research outputs
Top Co-Authors

Avatar

Youwei Yan

United States Military Academy

View shared research outputs
Researchain Logo
Decentralizing Knowledge